BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1551119)

  • 1. Loss of cis-diamminedichloroplatinum(II) resistance in human ovarian carcinoma cells selected for rhodamine 123 resistance.
    Zinkewich-PĂ©otti K; Andrews PA
    Cancer Res; 1992 Apr; 52(7):1902-6. PubMed ID: 1551119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial defects in cis-diamminedichloroplatinum(II)-resistant human ovarian carcinoma cells.
    Andrews PA; Albright KD
    Cancer Res; 1992 Apr; 52(7):1895-901. PubMed ID: 1551118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cross-resistance between cisplatin and antimony in a human ovarian carcinoma cell line.
    Naredi P; Heath DD; Enns RE; Howell SB
    Cancer Res; 1994 Dec; 54(24):6464-8. PubMed ID: 7987844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of carrier ligand in platinum resistance of human carcinoma cell lines.
    Schmidt W; Chaney SG
    Cancer Res; 1993 Feb; 53(4):799-805. PubMed ID: 8428361
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulation of cis-diamminedichloroplatinum(II) accumulation by modulation of passive permeability with genistein: an altered response in accumulation-defective resistant cells.
    Marverti G; Andrews PA
    Clin Cancer Res; 1996 Jun; 2(6):991-9. PubMed ID: 9816260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of lipid content, surface membrane fluidity, and temperature dependence of cis-diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Mann SC; Andrews PA; Howell SB
    Anticancer Res; 1988; 8(6):1211-5. PubMed ID: 3218956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Energetic characteristics of cisplatin resistant ovarian carcinoma cells.
    Dorward AM; Singh G
    Anticancer Res; 1996; 16(1):443-7. PubMed ID: 8615651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of mitochondria in cisplatin-resistant human ovarian carcinoma cells.
    Hirama M; Isonishi S; Yasuda M; Ishikawa H
    Oncol Rep; 2006 Nov; 16(5):997-1002. PubMed ID: 17016583
    [TBL] [Abstract][Full Text] [Related]  

  • 9. cis-Diamminedichloroplatinum(II) accumulation in sensitive and resistant human ovarian carcinoma cells.
    Andrews PA; Velury S; Mann SC; Howell SB
    Cancer Res; 1988 Jan; 48(1):68-73. PubMed ID: 3335000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
    Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
    Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cross-resistance to cisplatin in cells resistant to photofrin-mediated photodynamic therapy.
    Moorehead RA; Armstrong SG; Wilson BC; Singh G
    Cancer Res; 1994 May; 54(10):2556-9. PubMed ID: 7909492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II).
    Masuda H; Tanaka T; Matsuda H; Kusaba I
    Cancer Res; 1990 Mar; 50(6):1863-6. PubMed ID: 2306738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of lung resistance-related protein on the resistance to cisplatin in human ovarian cancer cell lines.
    Wang W; Ke S; Chen G; Gao Q; Wu S; Wang S; Zhou J; Yang X; Lu Y; Ma D
    Oncol Rep; 2004 Dec; 12(6):1365-70. PubMed ID: 15547764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple mechanisms of resistance to cis-diamminedichloroplatinum(II) in murine leukemia L1210 cells.
    Richon VM; Schulte N; Eastman A
    Cancer Res; 1987 Apr; 47(8):2056-61. PubMed ID: 3828995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. cis-Diamminedichloroplatinum(II) resistant human tumor cell lines are collaterally sensitive to PtCl4(Rh-123)2: evidence for mitochondrial involvement.
    Ara G; Kusumoto T; Korbut TT; Cullere-Luengo F; Teicher BA
    Cancer Res; 1994 Mar; 54(6):1497-502. PubMed ID: 8137254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single step selection of cis-diamminedichloroplatinum(II) resistant mutants from a human ovarian carcinoma cell line.
    McLaughlin K; Stephens I; McMahon N; Brown R
    Cancer Res; 1991 Apr; 51(8):2242-5. PubMed ID: 1901242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of a human nasopharyngeal carcinoma drug-resistant cell line CNE2/DDP and screening of drug-resistant genes].
    Jiang RD; Zhang LX; Yue W; Zhu YF; Lu HJ; Liu X; Cen XT; Guan XY; Li CH
    Ai Zheng; 2003 Apr; 22(4):337-45. PubMed ID: 12703984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin.
    Lau DH; Lewis AD; Ehsan MN; Sikic BI
    Cancer Res; 1991 Oct; 51(19):5181-7. PubMed ID: 1717140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between cell killing by cis-diamminedichloroplatinum(II) in six mammalian cell lines and binding of a cis-diamminedichloroplatinum(II)-DNA antiserum.
    Terheggen PM; Emondt JY; Floot BG; Dijkman R; Schrier PI; den Engelse L; Begg AC
    Cancer Res; 1990 Jun; 50(12):3556-61. PubMed ID: 2340504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multifactorial molecular mechanisms are involved in resistance of preirradiated human cervix carcinoma cells to cis-dichlorodiammineplatinum (II) and vincristine.
    Osmak M
    Neoplasma; 1993; 40(2):97-101. PubMed ID: 8102478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.